Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Combination With Carfilzomib, Daratumumab or Pomalidomide in Relapsed Multiple Myeloma
NCT04661137Phase 2Recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- Mar 2021
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in multiple myeloma (MM), sponsored by Hackensack Meridian Health. Primary endpoint: Overall Response Rate at 30 Months. Started Mar 2021; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04661137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661137.